- **Revenue** for the third quarter of 2025 increased **192.5%** year-over-year to **$12.8 million**, driven by higher SSi Mantra 3 unit sales.  **[1676163_0001213900-25-103137_ea026284701ex99-1_ssinnova.htm:0]** 
- The company reported a **net loss** of **$3.7 million**, or **$(0.02) per diluted share**, for the third quarter of 2025.  **[1676163_0001213900-25-103137_ea026284701ex99-1_ssinnova.htm:0]** 
- **SSi Mantra surgical robotic system installations** significantly increased by **350.0%** to **27** in Q3 2025 compared to Q3 2024, bringing the cumulative installed base to **127** systems.  **[1676163_0001213900-25-103137_ea026284701ex99-1_ssinnova.htm:0]** 
- SS Innovations completed a human factors validation study in September 2025, which is a key component for its planned **510(k) premarket notification to the FDA** in the fourth quarter of 2025.  **[1676163_0001213900-25-103137_ea026284701ex99-1_ssinnova.htm:0]** **[1676163_0001213900-25-103137_ea026284701ex99-1_ssinnova.htm:1]** 
- **Naveen Kumar Amar** was appointed as Chief Financial Officer on September 26, 2025.  **[1676163_0001213900-25-103137_ea026284701ex99-1_ssinnova.htm:1]**

SS Innovations International Reports Strong Q3 2025 Financial Results and CFO Appointment

- **SS Innovations International, Inc. (SSII)** reported significant revenue growth, increasing from **$5.6 million in 2023** to **$20.6 million in 2024**, a **251%** increase, and from **$8.1 million in 1H 2024** to **$15.1 million in 1H 2025**, an **86%** increase.  **[1676163_0001213900-25-098261_ea026102201ex99-1_ssinnova.htm:1]**  
- The company's **SSi Mantra Systems Installed** grew **191%** from **43 as of September 30, 2024**, to **125 as of September 30, 2025**, with **completed procedures increasing 182%** to **6,053** over the same period.  **[1676163_0001213900-25-098261_ea026102201ex99-1_ssinnova.htm:1]** **[1676163_0001213900-25-098261_ea026102201ex99-1_ssinnova.htm:7]** 
- **Gross margin** improved from **12.3% in 2023** to **40.9% in 2024**, and from **26.6% in 1H 2024** to **46.3% in 1H 2025**, with recurring revenue exceeding **10% of total revenue as of Q2 2025**.   
- SSII is expanding globally, with its SSi Mantra system marketed/approved in **8 countries** and anticipated US FDA and EU CE market clearances in **H1 2026**.  **[1676163_0001213900-25-098261_ea026102201ex99-1_ssinnova.htm:1]** **[1676163_0001213900-25-098261_ea026102201ex99-1_ssinnova.htm:7]**  
- The company differentiates its surgical robotic technology, including pioneering **telesurgery capabilities**, by offering it at approximately **one-third the cost of competing systems**.  **[1676163_0001213900-25-098261_ea026102201ex99-1_ssinnova.htm:5]** **[1676163_0001213900-25-098261_ea026102201ex99-1_ssinnova.htm:6]**

SS Innovations International, Inc. Reports Strong Growth and Global Expansion in October 2025 Presentation

- SS Innovations International, Inc. (SSII) successfully completed a **human factors validation study** for its SSi Mantra surgical robotic system at Johns Hopkins Hospital in September 2025.  **[1676163_0001213900-25-095851_ea026018501ex99-1_ssinnova.htm:0]** **[1676163_0001213900-25-095851_ea0260185-8k_ssinnova.htm:1]** 
- The company anticipates submitting a **510(k) premarket notification to the FDA in the fourth quarter of 2025** for the SSi Mantra.  **[1676163_0001213900-25-095851_ea026018501ex99-1_ssinnova.htm:0]** **[1676163_0001213900-25-095851_ea0260185-8k_ssinnova.htm:1]** 
- Potential FDA clearance for the SSi Mantra in the U.S. is expected in the **first half of 2026**, based on standard review timelines.  **[1676163_0001213900-25-095851_ea026018501ex99-1_ssinnova.htm:0]** 
- As of September 30, 2025, the SSi Mantra had a cumulative installed base of **125 systems** across six countries, with over **6,000 surgical procedures** performed.  **[1676163_0001213900-25-095851_ea026018501ex99-1_ssinnova.htm:0]**

SS Innovations International, Inc. Provides U.S. Regulatory Update for SSi Mantra Surgical Robotic System

- **SS Innovations International, Inc. (SSII)** announced the successful completion of the **world's first pediatric pyeloplasty telesurgery** utilizing its **SSi Mantra surgical robotic system** on **September 16, 2025**.  **[1676163_0001213900-25-087939_ea025749301ex99-1_ssinnov.htm:0]** **[1676163_0001213900-25-087939_ea0257493-8k_ssinnov.htm:1]** 
- The procedure was performed remotely by Dr. Chandra Mohan Vaddi from Gurugram, India, on a 16-month-old patient located nearly **1,000 miles away** in Hyderabad, India.  **[1676163_0001213900-25-087939_ea025749301ex99-1_ssinnov.htm:0]** 
- This milestone highlights the SSi Mantra's advanced capabilities in robotic telesurgery, with the system having been used for over **50 telesurgeries** across various specialties at distances up to **4,000 miles**.  **[1676163_0001213900-25-087939_ea025749301ex99-1_ssinnov.htm:0]** 
- The company plans to further expand the SSi Mantra's capabilities in pediatric robotic surgery through the development of smaller instrumentation, aiming to make robotic surgery affordable and accessible globally.  **[1676163_0001213900-25-087939_ea025749301ex99-1_ssinnov.htm:0]**

SS Innovations International (SSII)